🔗 Share this article

As the US proceeds with unprecedented revisions to its immunization guidelines, a particular individual has surfaced unexpectedly: Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who first made her name by questioning Covid shots during the pandemic and has zeroed in on alleged fatalities after Covid immunization in her brief position at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Vaccine Schedule

Public health authorities planned to announce sweeping changes to the childhood vaccination calendar recently, bringing the US with Denmark’s immunization schedule, sources say – a significant shift that would place the US at odds with many the global community with no evidence for benefit. This reveal has been delayed until the next year.

Instead of the top vaccines chief, Dr. Høeg is scheduled to address the audience at the event. She was newly appointed interim head of the FDA’s CDER, the fifth appointee to head the center this year.

A Shift at the FDA

This interim role could signify a closer partnership between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it points to a greater focus upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has often pushed for discontinuing specific childhood immunization guidelines in the US in order to be more like Denmark, a society with nationalized medicine and a citizenry about the size of the state of Wisconsin.

In her initial public appearances, she has persisted in emphasizing on vaccination policy – traditionally the responsibility of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Concerns Over Background

Høeg has no obvious experience in pharmaceutical research, oversight or management, which has been typical for previous directors of the CBER. She has served at the FDA as a senior adviser to the agency head and the vaccine center since earlier this year.

“She appears not to have the requisite experience” for overseeing the CDER, remarked Jonathan Howard. “She lacks experience running a scientific study. She is not versed in leading a major agency. She lacks background in drug approvals.”

Former heads of the center would “be deeply familiar with regulatory frameworks and the underlying principles of pharmaceutical innovation”, said Dr. Janet Woodcock. “Clearly, she has not acquired the kind of background that former directors who ran the center have had.”

The drug center has an immense portfolio at the agency, Woodcock emphasized.

“Many people just zeroes in on the innovative therapies, but the generic program approves thousands of off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and more, and every single one need to be managed,” she said. “The thing you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Furthermore, a major leadership aspect to the position, which oversees over 5,000 employees. “It’s a enormous administrative position, if you perform it correctly,” she added.

Response and Controversial Policies

In response to concerns about Dr. Høeg's qualifications and whether this assignment represents greater collaboration among agency officials on vaccines, a representative stated that the “inquiries are based on inaccurate assumptions”.

“Her experience matches the duties of her role,” the spokesperson explained, pointing to the period Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg inherits the commissioner’s controversial priority voucher program, a contentious expedited medication authorization process that allegedly worried her preceding directors. “By what process are these medications being selected for this voucher program? Who takes the calls?” Dr. Howard asked. “There’s a lot of confidentiality occurring at the regulatory body right now.”

Broadly speaking, he remarked, “the agency looks to be trending towards laxer regulations of most medications, except for shots.”

Public Past Work on Vaccines

Regarding immunizations, Dr. Høeg has a clearer, if troubling, history, Howard said. She published a research paper using unconfirmed crowd-sourced reports to determine the incidence of myocarditis following Covid immunization. She consulted for the Florida top health official Dr. Joseph Ladapo, who allegedly have modified findings to indicate Covid vaccinations are more dangerous than they are.

Part of her “policy goals” for the current government encompassed altering guidelines for novel immunizations and halting “unnecessary” immunizations, she stated after the election on a online show. At the FDA, Dr. Høeg has reportedly floated the idea of barring young men from getting Covid vaccines.

“She’s an all-around true believer who commences with her preconceived notions and works backwards to accommodate the evidence in a very deceptive, dishonest manner,” Howard said.

Taking Control and a “Revenge Tour”

Høeg joined fellow contrarians, {like|